Human VEGF-specific oligonucleotides

Details Human VEGF-specific oligonucleotides Human VEGF-specific oligonucleotides

1995-07-13

1997-08-26

Rories, Charles C. P.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

536 245, 536 235, 536 243, 536 2431, 536 2433, 435 6, A61K 3170, C07H 2100, C12N 510, C12Q 168

Patent

active

056611358

ABSTRACT:
Disclosed are methods of reducing neovascularization and of treating various disorders associated with neovascularization. These methods include administering to a tissue or subject a synthetic oligonucleotide specific for vascular endothelial growth factor nucleic acid effective in inhibiting the expression of vascular endothelial growth factor.

REFERENCES:
patent: 5219739 (1993-06-01), Tischer et al.
patent: 5225326 (1993-07-01), Brenner et al.
Wu Pong (1994) Pharmaceutical Technology 18:102-114.
Stull et al. (1995) Pharmaceutical Research 12:465-483.
Westermann et al. (1989) Biomed. Miochim. Acta. 48:85-93.
Milligan et al. (1993) J. Medicanal Chemistry 36:1923-1937.
Miller et al. (1994) Parasitology Today 10:92-97.
Weiss (1991) Science News 139:108-109.
Wagner (1994) Nature 372: 333-335.
Pierce et al. (1995) Investigative Ophthalmology & Visual Science 36:Abstract 3990.
Smith et al. (1995) Investigator Ophthalmology & Visual Science 36:Abstract 3992.
Monacci et al. (1993) American Journal Of Physiology 264:c995-c1002.
Garrido et al. (1993) Growth Factors 8:109-117.
E. Uhlmann et al. Chem. Rev. 90(4) (Jun. 1990) 543-84.
W. James Antivir Chem. & Chemother. 2(4)(91) 191-214.
J. Milligan et al. J. Med. Chem. 36(14) (Jul. 9, 1993) 1923-37.
C. Stein et al. Science 261 (80/20/93) 1004-12.
B. Tseng et al. Cancer Gene Therapy 1(1) (Mar. 1994) 65-71.
P. Westermann et al. Biomed. Biochim. Acta 48(1) (89)85-93.
J. Wetmur et al. Crit. Rev. Biochem. & Mol. Biol. 26(3/4)(91)227-59.
Uchida et al., (1995) Antisense Res. & Dev. 5(1):87 (Abstract OP-10).
Nomura et al., (1995) Antisense Res. & Dev. 5(1):91 (Abstract OP-18).
Michaelson (1948) Trans. Ophthalmol. Soc. U. K. 68:137-180.
Ashton et al. (1954) Br. J. Ophthalmol. 38:397-432.
Am. J. Ophthalmol. (1976) 81:383-396.
Knighton et al. (1983) Science 221:1283-1285.
Senger et al. (1986) Cancer Res. 46:5629-5632.
Folkman et al. (1987) Science 235:442-446.
Ophthalmol. (1991) 98:741-840 (Supplement).
Klagsbrun et al. (1991) Ann. Rev. Physiol 53:217-239.
Tischer et al. (1991) J. Biol. Chem. 266:11947-11954.
Claffey et al. (1992) J. Biol. Chem. 267:16317-16322.
Plate et al. (1992) Nature 359:845-848.
Plouet et al. (1992) Invest. Ophthalmol. Vis. Sci. 34:900.
Schweiki et al. (1992) Nature 359:843-845.
Adamis et al. (1993) Biochem. Biophys. Res. Commun. 193:631-638.
Adamis et al. (1993) Invest. Ophthalmol. Vis. Sci. 34:1440.
Kim et al. (1993) Nature 362:841-844.
Miller et al. (1993) Principles and Practice of Ophthalmology, W.B. Saunders, Philadelphia, p. 760.
Aiello et al. (1994) New Eng. J. Med. 331:1480-1487.
Aiello et al. (1994) Invest. Ophthalmol. Vis. Sci. 35:1868.
Anonymous (1994) Prevent Blindness America.
Bressler et al., Principles and Practices of Ophthalmology (eds. Albert and Jakobiac), W.B. Saunders Co., Philadelphia, PA) (1994) vol. 2.
Foster in Harrison's Principles of Internal Medicine (Isselbacher et al., eds.) McGraw-Hill, Inc., New York (1994) pp. 1994-1995.
Pierce et al. (1994) Int. Ophth. Clinics 34:121-148.
Simorre-Pinatel et al. (1994) Invest. Ophthalmol. Vis. Sci. 35:3393-3400.
Smith et al. (1994) Invest. Ophthalmol. Vis. Sci. 35:1442.
Smith et al. (1994) Invest. Ophthalmol. Vis. Sci. 35:101-111.
Focus (Jan. 6, 1995).
Ophthalmology World News (1995) p. 26.
Ophthalmology Times (Jan. 16-22, 1995).
Pierce et al. (1995) Proc. Natl. Acad. Sci. (USA) 92:905-909.

Affiliated with

Also associated with

Rating

Human VEGF-specific oligonucleotides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Human VEGF-specific oligonucleotides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human VEGF-specific oligonucleotides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1988612